1 of 1
Story summary
- BioMarin Pharmaceutical Inc. will acquire Amicus Therapeutics, Inc. for about $4.8 billion, expanding its rare-disease portfolio.
- Amicus shareholders will receive $14.50 per share, a 33% premium.
- The deal is expected to close in the second quarter of 2026, subject to approvals.
- Amicus’s therapies Galafold for Fabry disease and Pombiliti-Opfolda for Pompe disease could generate revenue for BioMarin.
- Morgan Stanley and J.P. Morgan are advising BioMarin on the deal.
